AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7808491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 7808491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine
Number of subjects: 0
Study 7808491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 0
Study 7808491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfin-pyrazone
Number of subjects: 0
Study 7808491 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus dipyridamole or sulfin-pyrazone
Number of subjects: 0
Study 7808491 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 2695129 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 490
Study 2695129 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 490
Study 2695129 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 490
Study 608010 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy plus surgery
Number of subjects: 100
Study 608010 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 100
Study 608010 — intervention group
Group type: COMPARATOR
Intervention: Surgery plus postoperative radiotherapy
Number of subjects: 100
Study 608010 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 100
Study 31969067 — intervention group
Group type: EXPERIMENTAL
Intervention: Desirability self‐affirmed feedback (DSF)
Number of subjects: 55
Study 31969067 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility self‐affirmed feedback (FSF)
Number of subjects: 55
Study 30518685 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inhaled carbon monoxide (iCO) at 100 ppm (cohort 1) or 200 ppm (cohort 2) for 90 minutes for up to 5 consecutive days
Number of subjects: 12
Study 30518685 — intervention group
Group type: COMPARATOR
Intervention: Placebo air
Number of subjects: 12
Study 26701762 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB)
Number of subjects: 591
Study 26701762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 591
Study 26701762 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB) with physical therapy
Number of subjects: 591
Study 25689563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Mediterranean diet with ω‐3 supplementation (KDO3)
Number of subjects: 34
Study 25689563 — intervention group
Group type: COMPARATOR
Intervention: Ketogenic Mediterranean diet without ω‐3 supplementation (KD)
Number of subjects: 34
Study 23317958 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 293
Study 23317958 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers and ex-smokers who smoked >20 cigarettes a day
Number of subjects: 293
Study 23317958 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 293
Study 20494360 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 69
Study 20494360 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 69
Study 20494360 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 69
Study 18230699 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary EtG
Number of subjects: 10
Study 18230699 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary EtS
Number of subjects: 10
Study 18230699 — intervention group
Group type: EXPERIMENTAL
Intervention: GTOL/5‐HIAA
Number of subjects: 10
Study 18230699 — intervention group
Group type: COMPARATOR
Intervention: Ethanol testing in urine
Number of subjects: 10
Study 15218006 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper half of endometrial cavity (Group I, n = 200)
Number of subjects: 400
Study 15218006 — intervention group
Group type: COMPARATOR
Intervention: Lower half of endometrial cavity (Group II, n = 200)
Number of subjects: 400
Study 12525911 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure haemorrhoidectomy
Number of subjects: 56
Study 9818657 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 70
Study 9818657 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Impact Measurement Scale 2 (AIMS2)
Number of subjects: 70
Study 9818657 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Outcome Study Short Form Health Survey (SF‐36)
Number of subjects: 70
Study 9818657 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Response Means (SRM) analysis
Number of subjects: 70
Study 9818657 — intervention group
Group type: COMPARATOR
Intervention: None of the instruments
Number of subjects: 70
Study 7631599 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy
Number of subjects: 26
Study 2654467 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsidan (0.1 mg/kg intravenously, then orally for 2-3 days every 3-4 hours, followed by 60-120 mg per 24 hours)
Number of subjects: 67
Study 2654467 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (control group)
Number of subjects: 67
Study 132326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 20
Study 132326 — intervention group
Group type: COMPARATOR
Intervention: Intra‐discal hydrocortisone
Number of subjects: 20
Study 31924485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oroesophageal (IOE) tube feeding
Number of subjects: 97
Study 31924485 — intervention group
Group type: COMPARATOR
Intervention: Continuous nasogastric tube feeding
Number of subjects: 97
Study 29858773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 5
Study 29858773 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic Psychotherapy
Number of subjects: 5
Study 27279083 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1007
Study 27279083 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 1007
Study 26323732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's anesthesia (group 2)
Number of subjects: 40
Study 26323732 — intervention group
Group type: COMPARATOR
Intervention: No sub‐Tenon's anesthesia (group 1)
Number of subjects: 40
Study 24381911 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal tramadol (2 mg/kg)
Number of subjects: 60
Study 24381911 — intervention group
Group type: COMPARATOR
Intervention: Isotonic solution (control)
Number of subjects: 60
Study 20854284 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 811
Study 20854284 — intervention group
Group type: COMPARATOR
Intervention: No Palivizumab
Number of subjects: 811
Study 19388886 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block
Number of subjects: 53
Study 19388886 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic analgesic regimen of paracetamol and diclofenac)
Number of subjects: 53
Study 16885230 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 38
Study 16885230 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 38
Study 14993578 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadate CD (MCD) 20 mg, 40 mg, 60 mg
Number of subjects: 0
Study 14993578 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadate CD (MCD) 40 mg, 60 mg
Number of subjects: 0
Study 14993578 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerta (CON) 18 mg, 36 mg, 54 mg
Number of subjects: 0
Study 14993578 — intervention group
Group type: COMPARATOR
Intervention: Metadate CD (MCD) and Concerta (CON)
Number of subjects: 0
Study 11713063 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of glaucoma (possible, probable, definite)
Number of subjects: 4744
Study 11713063 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history of glaucoma
Number of subjects: 4744
Study 11713063 — intervention group
Group type: EXPERIMENTAL
Intervention: Not attended an eye care provider in the last 2 years
Number of subjects: 4744
Study 9222707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension (2 x 2 g/day)
Number of subjects: 208
Study 9222707 — intervention group
Group type: COMPARATOR
Intervention: No additional medicine (Control)
Number of subjects: 208
Study 9222707 — intervention group
Group type: COMPARATOR
Intervention: Control (No sucralfate)
Number of subjects: 208
Study 9222707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 208
Study 7897780 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of a nasal decongestant
Number of subjects: 78
Study 3310717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed grass pollen allergens from rye grass, timothy grass, cultivated rye and velvet grass (administered daily for 1 year).
Number of subjects: 42
Study 3310717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered daily for 1 year).
Number of subjects: 42
Study 3310717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed grass pollen allergens (administered daily for 1 year).
Number of subjects: 42
Study 31529220 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigo naturalis (0.5-2.0 g daily)
Number of subjects: 86
Study 30442034 — intervention group
Group type: EXPERIMENTAL
Intervention: leave‐one‐out potential outcomes estimator
Number of subjects: 0
Study 30442034 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 27787540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral voriconazole (loading dose of 400 mg twice daily for 24 hours, followed by 200 mg twice daily for 20 days)
Number of subjects: 240
Study 27787540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral voriconazole
Number of subjects: 240
Study 27787540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 25330906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (new contraceptive method introduced, providers trained, community-wide information dissemination)
Number of subjects: 0
Study 25330906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 25330906 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22023889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-physician collaboration intervention involving interviews and pharmaceutical care for a year.
Number of subjects: 314
Study 22023889 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without pharmacist intervention).
Number of subjects: 314
Study 22023889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist interventions performed during the study.
Number of subjects: 314
Study 22023889 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of adverse drug reactions and drug interactions.
Number of subjects: 314
Study 22023889 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of drug interactions.
Number of subjects: 314
Study 20027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement of RVEDV
Number of subjects: 10
Study 20027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement of LVEDV
Number of subjects: 10
Study 20027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement of RV ejection fraction
Number of subjects: 10
Study 20027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement of RV mass
Number of subjects: 10
Study 20027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated measurement of RV mass
Number of subjects: 10
Study 20027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated measurement of LV end-diastolic volume (EDV)
Number of subjects: 10
Study 20027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual analysis
Number of subjects: 10
Study 20027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated analysis
Number of subjects: 10
Study 20027579 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reproducibility
Number of subjects: 10
Study 18752586 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated low-dose misoprostol
Number of subjects: 758
Study 18752586 — intervention group
Group type: COMPARATOR
Intervention: Standard induction method (vaginal dinoprostone followed by intravenous oxytocin or intravenous oxytocin alone)
Number of subjects: 758
Study 15497668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg (Sinopryl)
Number of subjects: 0
Study 15497668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril/hydrochlorothiazide 20 mg/12.5 mg (Sinoretik)
Number of subjects: 0
Study 11738168 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction external beam radiation therapy (8 Gy)
Number of subjects: 0
Study 11738168 — intervention group
Group type: COMPARATOR
Intervention: Various fractionated regimens
Number of subjects: 0
Study 9338613 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (Allergodil nasal spray)
Number of subjects: 14
Study 9338613 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Rhinocort Aqua)
Number of subjects: 14
Study 8179082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g intravenous at induction of anesthesia)
Number of subjects: 150
Study 8179082 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (1 g intravenous every 8 hours starting at induction, three times)
Number of subjects: 150
Study 3662317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremoval of the epithelium
Number of subjects: 0
Study 3662317 — intervention group
Group type: COMPARATOR
Intervention: Removal of the epithelium
Number of subjects: 0
Study 31642930 — intervention group
Group type: COMPARATOR
Intervention: No change in reminder signs throughout the intervention period
Number of subjects: 58
Study 31642930 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs changed weekly
Number of subjects: 58
Study 31642930 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs changed monthly
Number of subjects: 58
Study 30420367 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar mobilization therapy (PMT)
Number of subjects: 208
Study 30420367 — intervention group
Group type: COMPARATOR
Intervention: Control group (received PMT after the study period)
Number of subjects: 208
Study 27509602 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to specific acupuncture points, retained for 20 min, once every two days for 6 weeks.
Number of subjects: 90
Study 27509602 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam, 7.5 mg, once a day for 6 weeks.
Number of subjects: 90
Study 25275731 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-absorbing insoles (SAIs)
Number of subjects: 75
Study 25275731 — intervention group
Group type: COMPARATOR
Intervention: Usual insoles (Control)
Number of subjects: 75
Study 21741803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 54
Study 21741803 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 54
Study 21741803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco intake
Number of subjects: 54
Study 21741803 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 54
Study 20642070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse involvement in clinical trial implementation
Number of subjects: 0
Study 17321111 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/day for 6 weeks
Number of subjects: 24
Study 16321133 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) for five minutes while holding a static, semi-squat position
Number of subjects: 25
Study 16321133 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration) adopting the same weightbearing position for equal time
Number of subjects: 25
Study 11372795 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 g of PEG daily for 4 days
Number of subjects: 23
Study 11372795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11372795 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG treatment
Number of subjects: 23
Study 11372795 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG therapy
Number of subjects: 23
Study 11372795 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG laxative
Number of subjects: 23
Study 9230807 — intervention group
Group type: EXPERIMENTAL
Intervention: Handsewn ileal pouch-anal anastomosis (IPAA) with anal mucosa excised
Number of subjects: 41
Study 9230807 — intervention group
Group type: COMPARATOR
Intervention: Double-stapled ileal pouch-anal anastomosis (IPAA) with anal mucosa preserved
Number of subjects: 41
Study 9230807 — intervention group
Group type: COMPARATOR
Intervention: Double-stapled IPAA
Number of subjects: 41
Study 9230807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 41
Study 8434544 — intervention group
Group type: EXPERIMENTAL
Intervention: Slight photocoagulation (405 +/- 166 laser burns)
Number of subjects: 17
Study 8434544 — intervention group
Group type: COMPARATOR
Intervention: Heavy photocoagulation (1142 +/- 179 laser burns)
Number of subjects: 17
Study 8434544 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 17
Study 8434544 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of slight vs heavy photocoagulation
Number of subjects: 17
Study 3114710 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct extubation from intermittent mandatory ventilation rates of six to ten per minute
Number of subjects: 27
Study 3114710 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure through endotracheal tubes for six hours prior to extubation
Number of subjects: 27
Study 30624997 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotubation (Elgazzar and Alalfy technique)
Number of subjects: 0
Study 30624997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 31066646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose regimen containing voclosporin, MMF and steroid therapy
Number of subjects: 63
Study 31066646 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment with high dose MMF and steroids
Number of subjects: 63
Study 28495299 — intervention group
Group type: EXPERIMENTAL
Intervention: VC175
Number of subjects: 300
Study 28495299 — intervention group
Group type: COMPARATOR
Intervention: T380S
Number of subjects: 300
Study 26169946 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 51
Study 26169946 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study 26169946 — intervention group
Group type: COMPARATOR
Intervention: Leisure
Number of subjects: 51
Study 23438203 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated education programme in primary care
Number of subjects: 801
Study 23438203 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control group)
Number of subjects: 801
Study 21438794 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 929
Study 21438794 — intervention group
Group type: COMPARATOR
Intervention: SNRIs
Number of subjects: 929
Study 19228538 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative warm-up with standardized exercises
Number of subjects: 0
Study 19228538 — intervention group
Group type: COMPARATOR
Intervention: Fatigued group performance
Number of subjects: 0
Study 16517764 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF therapy (subcutaneous injections of 15 microg/kg per day for 5 days)
Number of subjects: 10
Study 16517764 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 10
Study 14656272 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel
Number of subjects: 0
Study 14656272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and paclitaxel
Number of subjects: 0
Study 11093843 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified inserts
Number of subjects: 1560
Study 11093843 — intervention group
Group type: COMPARATOR
Intervention: Unmodified inserts
Number of subjects: 1560
Study 9312920 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 38
Study 9312920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8312200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0
Study 8312200 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 0
Study 27819485 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (Ω3)
Number of subjects: 72
Study 27819485 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-Family Psychoeducational Psychotherapy (PEP) + Placebo
Number of subjects: 72
Study 27819485 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (Ω3) + Individual-Family Psychoeducational Psychotherapy (PEP)
Number of subjects: 72
Study 27819485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 27819485 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Ω3 + PEP)
Number of subjects: 72
Study 27819485 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (Ω3) monotherapy
Number of subjects: 72
Study 27819485 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP + Placebo
Number of subjects: 72
Study 27819485 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP
Number of subjects: 72
Study 29620396 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional-opportunities instruction
Number of subjects: 610
Study 29620396 — intervention group
Group type: COMPARATOR
Intervention: Standard admonition
Number of subjects: 610
Study 27454370 — intervention group
Group type: EXPERIMENTAL
Intervention: Family systems therapy
Number of subjects: 183
Study 27454370 — intervention group
Group type: COMPARATOR
Intervention: Women's Health Education
Number of subjects: 183
Study 25060157 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt enriched with 2 g of plant stanol ester (PS group)
Number of subjects: 90
Study 25060157 — intervention group
Group type: COMPARATOR
Intervention: Yoghurt drink without extra stanols (Control group)
Number of subjects: 90